Phospholipids as cancer biomarkers: Mass spectrometry‐based analysis. Issue 2 (8th June 2016)

• Record Type: Journal Article
• Authors: Bandu, Raju; Mok, Hyuck Jun; Kim, Kwang Pyo
• Is Part Of: Mass spectrometry reviews. Volume 37:Issue 2(2018)
• Page Start: 107
• Page End: 138
• Publication Date: 2016-06-08
• Subjects: phospholipids -- cancer -- biomarker -- tissues -- cells -- plasma -- serum -- mass spectrometry; Mass spectrometry -- Periodicals; 543
• DOI: 10.1002/mas.21510
• Languages: English
• ISSNs: 0277-7037

Abstract

Abstract : Lipids, particularly phospholipids (PLs), are key components of cellular membrane. PLs play important and diverse roles in cells such as chemical‐energy storage, cellular signaling, cell membranes, and cell–cell interactions in tissues. All these cellular processes are pertinent to cells that undergo transformation, cancer progression, and metastasis. Thus, there is a strong possibility that some classes of PLs are expected to present in cancer cells and tissues in cellular physiology. The mass spectrometric soft‐ionization techniques, electrospray ionization (ESI), and matrix‐assisted laser desorption/ionization (MALDI) are well‐established in the proteomics field, have been used for lipidomic analysis in cancer research. This review focused on the applications of mass spectrometry (MS) mainly on ESI‐MS and MALDI‐MS in the structural characterization, molecular composition and key roles of various PLs present in cancer cells, tissues, blood, and urine, and on their importance for cancer‐related problems as well as challenges for development of novel PL‐based biomarkers. The profiling of PLs helps to rationalize their functions in biological systems, and will also provide diagnostic information to elucidate mechanisms behind the control of cancer, diabetes, and neurodegenerative diseases. The investigation of cellular PLs with MS methods suggests new insights on various cancer diseases and clinical applications in the drug discovery and development of biomarkers for various PL‐related different cancer diseases. PL profiling in tissues, cells and body fluids also reflect the general condition of the whole organism and can indicate the existence of cancer and other diseases. PL profiling with MS opens new prospects to assess alterations of PLs in cancer, screening specific biomarkers and provide a basis for the development of novel therapeutic strategies. © 2016 Wiley Periodicals, Inc. Mass Spec Rev 37:107‐138, 2018